News: Actavis PLC (ACT)

ACT on New York Consolidated

265.39USD
19 Dec 2014
Price Change (% chg)

-- (--)
Prev Close
$265.39
Open
--
Day's High
--
Day's Low
--
Volume
10
Avg. Vol
3,102,057
52-wk High
$272.75
52-wk Low
$161.92

Search Stocks
Select another date:

Fri, Dec 19 2014

Spain's Almirall gains on report of Actavis interest

Dec 19 - Shares in Spanish drugmaker Almirall jumped 9 percent on Friday after a Bloomberg report of potential takeover interest from Actavis.

UPDATE 1-U.S. judge says Actavis must keep selling Alzheimer drug

Dec 11 - A U.S. judge said in a preliminary injunction on Thursday that Actavis Plc must continue to sell its Alzheimer's drug after a lawsuit alleged the company was trying to limit generic competition while it launched an extended-release version of the widely used medicine.

U.S. judge rules Actavis must continue to sell Alzheimer's drug

- A U.S. judge ruled on Thursday that Actavis Plc must continue to sell its Alzheimer's drug in a lawsuit alleging that the company was scheming to limit generic competition while it launched an extended-release version of the widely used drug.

U.S. judge rules Actavis must continue to sell Alzheimer's drug

- A U.S. judge ruled on Thursday that Actavis Plc must continue to sell its Alzheimer's drug in a lawsuit alleging that the company was scheming to limit generic competition while it launched an extended-release version of the widely used drug.

U.S. judge rules Actavis must continue to sell Alzheimer's drug

Dec 11 - A U.S. judge ruled on Thursday that Actavis Plc must continue to sell its Alzheimer's drug in a lawsuit alleging that the company was scheming to limit generic competition while it launched an extended-release version of the widely used drug.

FDA panel recommends approval for Actavis' antibiotic drug

- Actavis Plc said a panel advising the United States Food and Drug Administration recommended the approval of its antibiotic to treat two infections caused by drug-resistant bacteria.

FDA panel recommends approval for Actavis' antibiotic drug

Dec 5 - Actavis Plc said a panel advising the United States Food and Drug Administration recommended the approval of its antibiotic to treat two infections caused by drug-resistant bacteria.

Ackman's Pershing Square still holds 26.6 million Allergan shares

BOSTON, Nov 26 - Hedge fund manager William Ackman told investors in a letter that his firm still owns 26.6 million shares in Allergan Inc. which were valued at $5.6 billion one week after the Botox maker agreed to sell itself to rival pharmaceutical company Actavis Plc.

Actavis mulls job cuts, China expansion: Bloomberg

- Generic drugmaker Actavis Plc is planning to cut employees and expand in China, a Bloomberg report said citing an interview by Chief Executive Officer Brent Saunders on Bloomberg Television.

Actavis mulls job cuts, China expansion - Bloomberg

Nov 24 - Generic drugmaker Actavis Plc is planning to cut employees and expand in China, a Bloomberg report said citing an interview by Chief Executive Officer Brent Saunders on Bloomberg Television.

Select another date:
Search Stocks